3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
18
Carcinoma, Renal Cell
8
Neuroendocrine Tumors
6
Tuberous Sclerosis
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Seizures
2
Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma
2
Carcinoid Tumor
2
Astrocytoma
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis Complex-associated Refractory Seizures
1
Tuberous Sclerosis 2
1
Thymus Neoplasms
1
Stomach Diseases
1
Skin Neoplasms
1
Renal Cell Cancer Metastatic
1
Recurrence
1
Prostatic Neoplasms
1
Primary Non-metastatic Breast Cancer
1
Polycystic Kidney, Autosomal Dominant
1
Malignant Carcinoid Syndrome
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Interventions
esmolol
1
epigallocatechin gallate
1
contrast agent BR1
1
alpha-Tocopherol
1
Viusid
1
Sonazoid
1
Sodium Chloride
1
Simvastatin
1
Pentoxifylline
1
Metformin
1
Iodides
1
Everolimus
1
Dietary Supplements
1
Catechin
1
Aspirin
1
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Fibrosis
×
Everolimus
×
Clear all
NCT02134899
2018-12-10
EVERKYSTE
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
3 enrolled